Research News

A recent survey on the state of label management in the pharmaceutical industry undertaken by NiceLabel in cooperation with Pharmaceutical Manufacturing revealsthe challenges facing pharmaceutical manufacturers as they try to produce accurate, compliant labels, and highlights the increasing importance of a single, integrated label management system.

Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) and The National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare , New Delhi announced that they have signed an agreement for testing phytopharmaceutical, biologic and chemical entities developed by Sun Pharma against Zika, Chikungunya and Dengue viruses. Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems.

Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper from the European Society of Cardiology published in the June issue of European Heart Journal - Cardiovascular Pharmacotherapy.

Cells in nearly any part of the body can become cancerous and transform into tumors. Some, like skin cancer, are relatively accessible to treatment via surgery or radiation, which minimizes damage to healthy cells; others, like pancreatic cancer, are deep in the body and can only be reached by flooding the bloodstream with cell-killing chemotherapies that, ideally, shrink tumors by accumulating in their ill-formed blood and lymph vessels in higher amounts than in vessels of healthy tissues. To improve the low efficacy and toxic side effects of chemotherapies that rely on this passive accumulation, a team of researchers at the Wyss Institute at Harvard University, Boston Children's Hospital, and Harvard Medical School has developed a new drug delivery platform that uses safe, low-energy ultrasound waves to trigger the dispersal of chemotherapy-containing sustained-release nanoparticles precisely at tumor sites, resulting in a two-fold increase in targeting efficacy and a dramatic reduction in both tumor size and drug-related toxicity in mouse models of breast cancer.

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug–target binding in a physiological environment and at clinically-relevant concentrations. They revealed differences between the three drugs in the size and structure of the complexes formed, which may explain differences in the drugs’ clinical efficacy. This technique could help optimize future drug design.

Scientists have developed a new energy storage device that works with fluids in the human body and could lead to more durable and battery-free pacemakers and other implantable medical devices. The bio-friendly energy storage system called biological supercapacitor is powered by charged particles, or ions, from body fluids like blood serum and urine. Pacemakers - which help regulate abnormal heart rhythms - and other implantable devices have saved countless lives.

Cinnamon may lessen the risk of cardiovascular damage of a high-fat diet by activating the body's antioxidant and anti-inflammatory systems and slowing the fat-storing process, according to a preliminary animal study presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease 2017 Scientific Sessions

A drug used to treat bipolar disorder and other forms of depression may help to preserve brain function and prevent nerve cells from dying in people with a traumatic brain injury, according to a new Rutgers University study.

The global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.